Liposome Drug Delivery Market Size, Share, Trends, Growth Outlook

The Global Liposome Drug Delivery Market Size is estimated to register 9.2% growth over the forecast period from 2023 to 2030.

 

Liposome Drug Delivery Market Overview

The market is driven by ongoing research and development efforts to improve the stability, drug-loading capacity, and release kinetics of liposomal formulations. The rising prevalence of chronic diseases, such as cancer, cardiovascular diseases, and infectious diseases, has significantly driven the adoption of liposome drug delivery systems. The shift towards personalized medicine is leading to an increased interest in targeted drug delivery systems. Government initiatives and funding support for research in drug delivery technologies, including liposomes, contribute to market growth. The approval of new drugs and therapies utilizing liposome drug delivery systems by regulatory authorities further boosts market growth.

 

 

Market dynamics

Market trend: The rising occurrence of chronic diseases like cancer, cardiovascular issues, and infectious diseases is a key factor driving the use of liposome drug delivery systems.

The increasing incidence of chronic diseases, including cancer, cardiovascular diseases, and infectious diseases, has emerged as a pivotal driver for the adoption of liposome drug delivery systems. This trend is primarily fueled by the limitations and challenges associated with conventional drug delivery methods. Liposomes, as advanced drug delivery vehicles, address these challenges by offering a more targeted and controlled means of drug administration. Liposomes can be engineered to accumulate preferentially in tumor tissues through the enhanced permeability and retention (EPR) effect, minimizing damage to healthy cells and tissues. Moreover, the controlled release kinetics of drugs from liposomes contribute to optimizing therapeutic outcomes. The rising prevalence of chronic diseases has prompted pharmaceutical companies and researchers to explore and invest in liposome-based drug delivery technologies.

 

Market driver: Regulatory approval for new drugs utilizing liposome drug delivery systems is instrumental in driving market expansion.

The approval of new drugs and therapies incorporating liposome drug delivery systems by regulatory authorities plays a crucial role in propelling market growth. Companies are more inclined to allocate resources and investments toward research and development efforts focused on expanding the applications of liposomes across various therapeutic areas. Furthermore, regulatory approvals provide a competitive advantage to companies operating in the liposome drug delivery market. Collaborations between pharmaceutical companies, research institutions, and technology developers may increase, fostering a collaborative ecosystem focused on advancing liposomal technologies for drug delivery.

 

Market Opportunity:  Advances in nanomedicine technology have played a major role in the expansion of the liposome drug delivery market.

Technological advancements in the field of nanomedicine have significantly contributed to the growth of the liposome drug delivery market. Nanomedicine allows for a more precise and targeted approach to drug delivery, leveraging the unique properties of nanoscale materials. The ability to engineer liposomes with greater precision and predictability allows for the creation of drug delivery systems that can navigate biological barriers and deliver drugs to specific cells or tissues. Researchers can explore novel combinations of therapeutic agents encapsulated within liposomes, facilitating synergistic effects and improving treatment outcomes.

 

Market share analysis: Liposomal paclitaxel stands out as the rapidly growing technology within liposome drug delivery.

Liposomal paclitaxel is the fastest-growing liposome drug delivery technology. It is more effective than traditional paclitaxel in treating a variety of cancers, including breast, lung, and ovarian cancers. This heightened efficacy is attributed to liposomal paclitaxel's ability to deliver the drug directly to the tumor site, where it can more effectively eliminate cancer cells. Additionally, liposomal paclitaxel exhibits lower toxicity compared to traditional paclitaxel, resulting in a reduced likelihood of patients experiencing side effects such as hair loss, neuropathy, and fatigue. Moreover, liposomal paclitaxel is administered less frequently than traditional paclitaxel, enhancing its convenience for patients in terms of medication management.

 

Stealth liposome technology is the dominant market segment within liposome drug delivery.

Stealth liposome technology constitutes the largest market segment in liposome drug delivery. Stealth liposomes possess the capability to evade the reticuloendothelial system (RES), the body's natural defense system against foreign particles. This unique characteristic enables stealth liposomes to circulate in the bloodstream for extended periods, enhancing their ability to deliver drugs more effectively to the target site. Importantly, stealth liposomes are less prone to being taken up by non-target cells, thereby reducing the likelihood of side effects. Furthermore, the versatility of stealth liposomes allows for targeted delivery to tumors through the use of specific ligands.

 

Liposome Drug Delivery Market Segmentation

By Type

• Liposomal Paclitaxel
• Liposomal Doxorubicin
• Liposomal Amphotericin B
• Others 

By Technique

• Stealth Liposome Technology
• Non-PEGylated Liposome Technology 
• DepoFoam Liposome Technology 

By Indication

• Fungal Infections
• Cancer Therapeutics
• Pain Management
• Viral Vaccines
• Others

By Region

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Spain, Italy, Others)
• Asia Pacific (China, India, Japan, South Korea, Australia, Others)
• Latin America (Brazil, Argentina, Others)
• Middle East and Africa (Saudi Arabia, UAE, Kuwait, Other Middle East, South Africa, Nigeria, Other Africa)

 

Liposome Drug Delivery companies

• Gilead Sciences Inc
• Takeda Pharmaceutical Company Limited
• Pacira BioSciences Inc
• Spectrum Pharmaceuticals Inc
• Luye Pharma Group
• Johnson and Johnson
• Ipsen Pharma
• Celsion Corporation
• Novartis AG
• Sun Pharmaceutical
• Acrotech Biopharma, Inc
• Teva Pharmaceutical Industries Ltd

 

*List not exhaustive

 

Liposome Drug Delivery Market Outlook 2023

1 Market Overview

1.1 Introduction to the Liposome Drug Delivery Market

1.2 Scope of the Study

1.3 Research Objective

1.3.1 Key Market Scope and Segments

1.3.2 Players Covered

1.3.3 Years Considered

 

2 Executive Summary

2.1 2023 Liposome Drug Delivery Industry- Market Statistics

3 Market Dynamics

3.1 Market Drivers

3.2 Market Challenges

3.3 Market Opportunities

3.4 Market Trends

 

4 Market Factor Analysis

4.1 Porter’s Five Forces

4.2 Market Entropy

4.2.1 Global Liposome Drug Delivery Market Companies with Area Served

4.2.2 Products Offerings Global Liposome Drug Delivery Market

 

5 COVID-19 Impact Analysis and Outlook Scenarios

5.1.1 Covid-19 Impact Analysis

5.1.2 post-COVID-19 Scenario- Low Growth Case

5.1.3 post-COVID-19 Scenario- Reference Growth Case

5.1.4 post-COVID-19 Scenario- Low Growth Case

 

6 Global Liposome Drug Delivery Market Trends

6.1 Global Liposome Drug Delivery Revenue (USD Million) and CAGR (%) by Type (2018-2030)

6.2 Global Liposome Drug Delivery Revenue (USD Million) and CAGR (%) by Applications (2018-2030)

6.3 Global Liposome Drug Delivery Revenue (USD Million) and CAGR (%) by regions (2018-2030)

 

7 Global Liposome Drug Delivery Market Revenue (USD Million) by Type, and Applications (2018-2022)

7.1 Global Liposome Drug Delivery Revenue (USD Million) by Type (2018-2022)

7.1.1 Global Liposome Drug Delivery Revenue (USD Million), Market Share (%) by Type (2018-2022)

7.2 Global Liposome Drug Delivery Revenue (USD Million) by Applications (2018-2022)

7.2.1 Global Liposome Drug Delivery Revenue (USD Million), Market Share (%) by Applications (2018-2022)

 

8 Global Liposome Drug Delivery Development Regional Status and Outlook

8.1 Global Liposome Drug Delivery Revenue (USD Million) By Regions (2018-2022)

8.2 North America Liposome Drug Delivery Revenue (USD Million) by Type, and Application (2018-2022)

8.2.1 North America Liposome Drug Delivery Revenue (USD Million) by Country (2018-2022)

8.2.2 North America Liposome Drug Delivery Revenue (USD Million) by Type (2018-2022)

8.2.3 North America Liposome Drug Delivery Revenue (USD Million) by Applications (2018-2022)

8.3 Europe Liposome Drug Delivery Revenue (USD Million), by Type, and Applications (USD Million) (2018-2022)

8.3.1 Europe Liposome Drug Delivery Revenue (USD Million), by Country (2018-2022)

8.3.2 Europe Liposome Drug Delivery Revenue (USD Million) by Type (2018-2022)

8.3.3 Europe Liposome Drug Delivery Revenue (USD Million) by Applications (2018-2022)

8.4 Asia Pacific Liposome Drug Delivery Revenue (USD Million), and Revenue (USD Million) by Type, and Applications (2018-2022)

8.4.1 Asia Pacific Liposome Drug Delivery Revenue (USD Million) by Country (2018-2022)

8.4.2 Asia Pacific Liposome Drug Delivery Revenue (USD Million) by Type (2018-2022)

8.4.3 Asia Pacific Liposome Drug Delivery Revenue (USD Million) by Applications (2018-2022)

8.5 South America Liposome Drug Delivery Revenue (USD Million), by Type, and Applications (2018-2022)

8.5.1 South America Liposome Drug Delivery Revenue (USD Million), by Country (2018-2022)

8.5.2 South America Liposome Drug Delivery Revenue (USD Million) by Type (2018-2022)

8.5.3 South America Liposome Drug Delivery Revenue (USD Million) by Applications (2018-2022)

8.6 Middle East and Africa Liposome Drug Delivery Revenue (USD Million), by Type, Technology, Application, Thickness (2018-2022)

8.6.1 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) by Country (2018-2022)

8.6.2 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) by Type (2018-2022)

8.6.3 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) by Applications (2018-2022)

 

9 Company Profiles

 

10 Global Liposome Drug Delivery Market Revenue (USD Million), by Type, and Applications (2023-2030)

10.1 Global Liposome Drug Delivery Revenue (USD Million) and Market Share (%) by Type (2023-2030)

10.1.1 Global Liposome Drug Delivery Revenue (USD Million), and Market Share (%) by Type (2023-2030)

10.2 Global Liposome Drug Delivery Revenue (USD Million) and Market Share (%) by Applications (2023-2030)

10.2.1 Global Liposome Drug Delivery Revenue (USD Million), and Market Share (%) by Applications (2023-2030)

 

11 Global Liposome Drug Delivery Development Regional Status and Outlook Forecast

11.1 Global Liposome Drug Delivery Revenue (USD Million) By Regions (2023-2030)

11.2 North America Liposome Drug Delivery Revenue (USD Million) by Type, and Applications (2023-2030)

11.2.1 North America Liposome Drug Delivery Revenue (USD) Million by Country (2023-2030)

11.2.2 North America Liposome Drug Delivery Revenue (USD Million), by Type (2023-2030)

11.2.3 North America Liposome Drug Delivery Revenue (USD Million), Market Share (%) by Applications (2023-2030)

11.3 Europe Liposome Drug Delivery Revenue (USD Million), by Type, and Applications (2023-2030)

11.3.1 Europe Liposome Drug Delivery Revenue (USD Million), by Country (2023-2030)

11.3.2 Europe Liposome Drug Delivery Revenue (USD Million), by Type (2023-2030)

11.3.3 Europe Liposome Drug Delivery Revenue (USD Million), by Applications (2023-2030)

11.4 Asia Pacific Liposome Drug Delivery Revenue (USD Million) by Type, and Applications (2023-2030)

11.4.1 Asia Pacific Liposome Drug Delivery Revenue (USD Million), by Country (2023-2030)

11.4.2 Asia Pacific Liposome Drug Delivery Revenue (USD Million), by Type (2023-2030)

11.4.3 Asia Pacific Liposome Drug Delivery Revenue (USD Million), by Applications (2023-2030)

11.5 South America Liposome Drug Delivery Revenue (USD Million), by Type, and Applications (2023-2030)

11.5.1 South America Liposome Drug Delivery Revenue (USD Million), by Country (2023-2030)

11.5.2 South America Liposome Drug Delivery Revenue (USD Million), by Type (2023-2030)

11.5.3 South America Liposome Drug Delivery Revenue (USD Million), by Applications (2023-2030)

11.6 Middle East and Africa Liposome Drug Delivery Revenue (USD Million), by Type, and Applications (2023-2030)

11.6.1 Middle East and Africa Liposome Drug Delivery Revenue (USD Million), by region (2023-2030)

11.6.2 Middle East and Africa Liposome Drug Delivery Revenue (USD Million), by Type (2023-2030)

11.6.3 Middle East and Africa Liposome Drug Delivery Revenue (USD Million), by Applications (2023-2030)

 

12 Methodology and Data Sources

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Sources

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Disclaimer

 

List of Tables

Table 1 Market Segmentation Analysis

Table 2 Global Liposome Drug Delivery Market Companies with Areas Served

Table 3 Products Offerings Global Liposome Drug Delivery Market

Table 4 Low Growth Scenario Forecasts

Table 5 Reference Case Growth Scenario

Table 6 High Growth Case Scenario

Table 7 Global Liposome Drug Delivery Revenue (USD Million) And CAGR (%) By Type (2018-2030)

Table 8 Global Liposome Drug Delivery Revenue (USD Million) And CAGR (%) By Applications (2018-2030)

Table 9 Global Liposome Drug Delivery Revenue (USD Million) And CAGR (%) By Regions (2018-2030)

Table 10 Global Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Table 11 Global Liposome Drug Delivery Revenue Market Share (%) By Type (2018-2022)

Table 12 Global Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Table 13 Global Liposome Drug Delivery Revenue Market Share (%) By Applications (2018-2022)

Table 14 Global Liposome Drug Delivery Market Revenue (USD Million) By Regions (2018-2022)

Table 15 Global Liposome Drug Delivery Market Share (%) By Regions (2018-2022)

Table 16 North America Liposome Drug Delivery Revenue (USD Million) By Country (2018-2022)

Table 17 North America Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Table 18 North America Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Table 19 Europe Liposome Drug Delivery Revenue (USD Million) By Country (2018-2022)

Table 20 Europe Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Table 21 Europe Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Table 22 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Country (2018-2022)

Table 23 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Table 24 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Table 25 South America Liposome Drug Delivery Revenue (USD Million) By Country (2018-2022)

Table 26 South America Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Table 27 South America Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Table 28 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Region (2018-2022)

Table 29 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Table 30 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Table 31 Financial Analysis

Table 32 Global Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Table 33 Global Liposome Drug Delivery Revenue Market Share (%) By Type (2023-2030)

Table 34 Global Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Table 35 Global Liposome Drug Delivery Revenue Market Share (%) By Applications (2023-2030)

Table 36 Global Liposome Drug Delivery Market Revenue (USD Million), And Revenue (USD Million) By Regions (2023-2030)

Table 37 North America Liposome Drug Delivery Revenue (USD)By Country (2023-2030)

Table 38 North America Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Table 39 North America Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Table 40 Europe Liposome Drug Delivery Revenue (USD Million) By Country (2023-2030)

Table 41 Europe Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Table 42 Europe Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Table 43 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Country (2023-2030)

Table 44 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Table 45 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Table 46 South America Liposome Drug Delivery Revenue (USD Million) By Country (2023-2030)

Table 47 South America Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Table 48 South America Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Table 49 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Region (2023-2030)

Table 50 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Region (2023-2030)

Table 51 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Table 52 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Table 53 Research Programs/Design for This Report

Table 54 Key Data Information from Secondary Sources

Table 55 Key Data Information from Primary Sources

 

List of Figures

Figure 1 Market Scope

Figure 2 Porter’s Five Forces

Figure 3 Global Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Figure 4 Global Liposome Drug Delivery Revenue Market Share (%) By Type (2022)

Figure 5 Global Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Figure 6 Global Liposome Drug Delivery Revenue Market Share (%) By Applications (2022)

Figure 7 Global Liposome Drug Delivery Market Revenue (USD Million) By Regions (2018-2022)

Figure 8 Global Liposome Drug Delivery Market Share (%) By Regions (2022)

Figure 9 North America Liposome Drug Delivery Revenue (USD Million) By Country (2018-2022)

Figure 10 North America Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Figure 11 North America Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Figure 12 Europe Liposome Drug Delivery Revenue (USD Million) By Country (2018-2022)

Figure 13 Europe Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Figure 14 Europe Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Figure 15 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Country (2018-2022)

Figure 16 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Figure 17 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Figure 18 South America Liposome Drug Delivery Revenue (USD Million) By Country (2018-2022)

Figure 19 South America Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Figure 20 South America Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Figure 21 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Region (2018-2022)

Figure 22 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Type (2018-2022)

Figure 23 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Applications (2018-2022)

Figure 24 Global Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Figure 25 Global Liposome Drug Delivery Revenue Market Share (%) By Type (2030)

Figure 26 Global Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Figure 27 Global Liposome Drug Delivery Revenue Market Share (%) By Applications (2030)

Figure 28 Global Liposome Drug Delivery Market Revenue (USD Million) By Regions (2023-2030)

Figure 29 North America Liposome Drug Delivery Revenue (USD Million) By Country (2023-2030)

Figure 30 North America Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Figure 31 North America Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Figure 32 Europe Liposome Drug Delivery Revenue (USD Million) By Country (2023-2030)

Figure 33 Europe Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Figure 34 Europe Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Figure 35 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Country (2023-2030)

Figure 36 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Figure 37 Asia Pacific Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Figure 38 South America Liposome Drug Delivery Revenue (USD Million) By Country (2023-2030)

Figure 39 South America Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Figure 40 South America Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Figure 41 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Region (2023-2030)

Figure 42 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Region (2023-2030)

Figure 43 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Type (2023-2030)

Figure 44 Middle East and Africa Liposome Drug Delivery Revenue (USD Million) By Applications (2023-2030)

Figure 45 Bottom-Up and Top-Down Approaches for This Report

Figure 46 Data Triangulation

 

Liposome Drug Delivery Market Segmentation

By Type

• Liposomal Paclitaxel
• Liposomal Doxorubicin
• Liposomal Amphotericin B
• Others 

By Technique

• Stealth Liposome Technology
• Non-PEGylated Liposome Technology 
• DepoFoam Liposome Technology 

By Indication

• Fungal Infections
• Cancer Therapeutics
• Pain Management
• Viral Vaccines
• Others

By Region

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Spain, Italy, Others)
• Asia Pacific (China, India, Japan, South Korea, Australia, Others)
• Latin America (Brazil, Argentina, Others)
• Middle East and Africa (Saudi Arabia, UAE, Kuwait, Other Middle East, South Africa, Nigeria, Other Africa)